Skip to main content

Table 1 Details of the included trials

From: Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis

Study (Trail)

Publication Year

Study duration

Original nation

Median follow-up

No. of patient(n)

ER status

Primary endpoints

Chemotherapy strategy

Regimen

West [8]

2011

Unknow

Canada

Unknow

111

Negative

pCR

NAC

FEC or TET

Seo [9]

2013

2004–2011

Korea

Unknow

153

Both

pCR

NAC

AC or ACT or AD

Lee [10]

2013

2000–2009

Korea

Unknow

175

Both

pCR

NAC

AC or ACT

Denkert [11]*

2010

1999–2001

Germany

Unknow

218

Both

pCR

NAC

ACT

Denkert [11]*

2010

2002–2005

Germany

Unknow

840

Both

pCR

NAC

TAC or TAC followed by vinorelbine and capecitabine

Denkert [12]

2015

Unknow

Germany

Unknow

580

Negative

pCR

Unknow

1:1 to PM or PMCb

Watanabe [13]

2018

2008–2016

Japan

26.1 m

197

Both

pCR

NAC

Anthracycline- or taxane- or anthracycline- plus taxane-based

Galvez [14]

2018

2003–2014

Peru

Unknow

435

Both

pCR

NAC

ACP or AC

Hida [15]

2016

2007–2014

Japan

Unknow

159

Negative

pCR

NAC

Unknow

Denkert [6]

2018

Unknow

Germany

Unknow

3771

Both

pCR, OS

NAC

Docetaxel- or paclitaxel- or nab-paclitaxel-based

Hwang [16]

2019

2004–2013

Korea

60.1 m

248

Both

pCR

NAC

Anthracycline- plus taxane-based

Kim [17]

2016

2004–2011

Korea

6.4y

688

Negative

OS

NAC

AC or ACT or ACP

Sønderstrup [18]

2019

1997–2011

Denmark

5.8y

399

Both

OS

Unknow

Unknow

Pruneri [19]

2016

1995–2010

Switzerland

8.2y

897

Negative

OS

AC

CMF, CMF + AC

Pruneri [20]

2016

Unknow

Italy

6.9y

647

Negative

OS

AC

1:1 to CM or no-CM

Tian [21]

2016

2008–2012

China

4y

372

Negative

OS

AC

Anthracycline- or anthracycline- plus taxanes-based

Adams [22]

2014

Unknow

USA

10.6y

481

Negative

OS

NAC

ACT or ACP

Loi [5]

2014

Unknow

Belgium

62 m

934

Both

OS

NAC

Docetaxel or vinorelbine followed by FEC

Kochi [23]

2018

Unknow

Japan

Unknow

40

Both

OS

NAC

Anthracycline- plus taxane-based

Dieci [24]

2015

Unknow

France

12.7y

781

Both

OS

AC

Anthracycline-based

Luen [25]

2019

Unknow

Australia

6y

375

Negative

OS

NAC

Unknow

Luen [26]

2017

Unknow

Australia

50 m

678

Negative

OS

AC

1:1 to trastuzumab and docetaxel plus either pertuzumab or placebo

Burugu [27]

2017

1989–2002

Canada

13y

2497

Both

Others

AC

Unknow

  1. *This article is divided into two researches due to different regimen
  2. Abbreviations: pCR, pathological complete response; OS, overall survival; NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy; TNBC, triple-negative breast cancer; HER2 + BC, human epidermal growth factor receptor 2 positive breast cancer
  3. Regimen explanation: FEC: fluorouracil, epirubicin, and cyclophosphamide; TET: docetaxel followed by epirubicin plus docetaxel; AC: doxorubicin and cyclophosphamide; ACT: AC followed by docetaxel; AD: doxorubicin and docetaxel; TAC: docetaxel, doxorubicin, and cyclophosphamide; PM: Paclitaxel and non-pegylated liposomal doxorubicin; PMCb: Paclitaxel and non-pegylated liposomal doxorubicin followed by carboplatin; TP: paclitaxel plus platinum; ACP: doxorubicin and cyclophosphamide followed by paclitaxel; CAF: cyclophosphamide, adriamycin and fluorouracil; CMF: cyclophosphamide, methotrexate and fluorouracil; CM: cyclophosphamide plus methotrexate